Effects of Recurrent PE on Women and Offspring (RPOH)

December 7, 2021 updated by: Dunjin Chen

The Effects of Recurrent PE on Women and Offspring's Health

The purpose of this study is to evaluate the risk factors of recurrent preeclampsia and compare the short-term and long-term adverse outcomes of women and their offspring.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The investigators collected women delivered twice in a row in our hospital. The investigators divided these pregnant women into three groups. Women in the first group did not complicate preeclampsia at both deliveries; Women in the second group complicated preeclampsia at the first delivery or at the second delivery; women in the third group complicated preeclampsia at two deliveries. The investigators explore the risk factors of recurrent preeclampsia and measure blood pressure, blood lipids, thyroid function, glycosylated hemoglobin, ALT, AST, et al. in one year, three years, and five years after the second delivery.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Guangzhou, China, 510150
        • Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University
        • Contact:
          • Dunjin Chen
        • Contact:
          • Lili Du

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

19 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

women with at least twice of delivery history are divided into three groups, control group refers to women without preeclampsia history, the second group refers to women complicated with preeclampsia at the first delivery or at the second delivery, the third group refers to women complicated with preeclampsia at two deliveries.

Description

Inclusion Criteria:

  • women with at least twice of delivery history

Exclusion Criteria:

  • women with chronic hypertension

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
control
pregnancy without preeclampsia
Other: blood pressure,BMI, blood sample
Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
preeclampsia
pregnancy complicated with preeclampsia at the first delivery or at the second delivery
Other: blood pressure,BMI, blood sample
Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
recurrent preeclampsia
pregnancy complicated with preeclampsia at two deliveries
Other: blood pressure,BMI, blood sample
Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
blood pressure and hypertension of women
Time Frame: 1year after the second deliver
blood pressure ≥140/90 mmHg
1year after the second deliver
blood pressure and hypertension of women
Time Frame: 3 years after the second deliver
blood pressure ≥140/90 mmHg
3 years after the second deliver
blood pressure and hypertension of women
Time Frame: 5 years after the second deliver
blood pressure ≥140/90 mmHg
5 years after the second deliver
blood pressure and hypertension of offspring
Time Frame: 1 year old
blood pressure≥140/90 mmHg
1 year old
blood pressure and hypertension of offspring
Time Frame: 3 years old
blood pressure≥140/90 mmHg
3 years old
blood pressure and hypertension of offspring
Time Frame: 5 years old
blood pressure≥140/90 mmHg
5 years old
level of glycosylated hemoglobin in blood
Time Frame: 1 year after the second deliver
women
1 year after the second deliver
level of glycosylated hemoglobin in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of glycosylated hemoglobin in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver
level of cholesterol, LDL, HDL, VLDL-C in blood
Time Frame: 1 year after the second deliver
women
1 year after the second deliver
level of cholesterol, LDL, HDL, VLDL-C in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of cholesterol, LDL, HDL, VLDL-C in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver
level of FT3,FT4, and hTSH in blood
Time Frame: 1year after the second deliver
women
1year after the second deliver
level of FT3,FT4, and hTSH in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of FT3,FT4, and hTSH in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver
level of AST and ALT in blood
Time Frame: 1year after the second deliver
women
1year after the second deliver
level of AST and ALT in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of AST and ALT in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
BMI of offspring
Time Frame: 1 year old
weight(kg)/height(m)2
1 year old
BMI of offspring
Time Frame: 3 years old
weight(kg)/height(m)2
3 years old
BMI of offspring
Time Frame: 5 years old
weight(kg)/height(m)2
5 years old
level of insulin in blood
Time Frame: 1year after the second deliver
women
1year after the second deliver
level of insulin in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of insulin in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver
level of fructosamine in blood
Time Frame: 1year after the second deliver
women
1year after the second deliver
level of fructosamine in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of fructosamine in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver
level of AI37℃、AI4℃、PRA、ALD、AngII in blood
Time Frame: 1 year after the second deliver
women
1 year after the second deliver
level of AI37℃、AI4℃、PRA、ALD、AngII in blood
Time Frame: 3 years after the second deliver
women
3 years after the second deliver
level of AI37℃、AI4℃、PRA、ALD、AngII in blood
Time Frame: 5 years after the second deliver
women
5 years after the second deliver

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Dunjin Chen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2022

Primary Completion (ANTICIPATED)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2024

Study Completion (ANTICIPATED)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 8, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 23, 2021

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 24, 2021

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 8, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 7, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 81830045

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings